Atlantic Research Group’s Post

Vaxxinity, unveiled intriguing findings at the 2024 American Academy of Neurology conference concerning their investigational active immunotherapy, UB-312. The study aimed to assess target engagement in cerebrospinal fluid (CSF) samples of Parkinson's disease (PD) patients using the Amprion R&D aSyn seed amplification assay (aSyn-SAA). UB-312 represents a promising direction in PD treatment by targeting pathological forms of alpha-synuclein (aSyn), a pivotal protein linked to the advancement of synucleinopathies. Unlike traditional methods, UB-312 endeavors to stimulate antibodies that specifically identify and counteract these detrimental aSyn variants, potentially arresting or decelerating the neurodegenerative mechanisms underlying PD. Read more @ https://lnkd.in/gEBn5M8f #Vaxxinity #UB312 #ParkinsonsDisease #NeurologyConference #Immunotherapy #AlphaSynuclein #CSFsamples #Neurodegeneration #Synucleinopathies #PDResearch

In #BreakingNews in the Alzheimer's Disease space, Roche is granted breakthrough device designation for its Alzheimer's Disease diagnostic blood test, Elecsys pTau217. The test was co-developed with Eli Lilly and Company, and is described to "works to identify the presence or absence of amyloid pathology". In short, a positive 'pTau217' plasma biomarker presence would indicate "high likelihood of having a positive amyloid positron emission tomography (PET)/cerebrospinal fluid (CSF) result" and will allow earlier diagnosis and interventions. https://lnkd.in/eAAs629q #AlzheimersDisease #Roche #EliLilly #NeurodegenerativeDisease #Neurology #Neuroscience #Innovation #Breakthroughs #Biomarkers #Diagnostics #RegulatoryAffairs #Pharma #Healthcare

I am excited to share our latest Neurology Update for the Panel of Neuroimmunology. 🧠 👇 Learn about Neuromyelitis Optica Spectrum Disorders (NMOSD) and the latest recommendations for diagnosis and treatment from the Neuromyelitis Optica Study Group (NEMOS). Discover how this rare autoimmune disease affects the central nervous system and the advancements in therapy management. Stay informed on the latest immunotherapies approved for NMOSD. #NMOSD #Autoimmune_disease #NEMOS #EAN #RRFS #Neuroimmunology_Panel

Find key insights about the future of medicine from IQVIA Institute's annual trend report in the post below.

Join InnoSer in raising awareness for Parkinson’s disease!  April 11th marks Parkinson’s disease awareness day, with the whole month of April being dedicated to raising awareness of this devastating neurodegenerative disease. The global prevalence of Parkinson’s disease has doubled in the last 25 years, leading to global increases in disabilities and death as a result of this neurological disease.  Current Parkinson’s disease therapies focus on relieving disease symptoms rather than preventing disease progression. New and more powerful therapeutic approaches targeting disease pathology are needed to address the disease development and severity of Parkinson’s disease.  Multiple in vitro and in vivo models have been generated to evaluate the efficacy and safety of such novel treatments. However, different experimental models recapitulate distinct pathophysiological features of Parkinson’s disease. Therefore, selecting the most appropriate model for your specific research question is crucial to advancing the development of targeted therapeutics.  Together with our neurology study directors Jolien B. and Thomas Vogels we have recently put together a blog post discussing all available in vitro and in vivo Parkinson’s disease models that InnoSer offers. Click here to discover how your research can benefit from InnoSer’s preclinical expertise and experience in modelling neurodegenerative diseases such as Parkinson’s: https://lnkd.in/ePZzn5dF  #ParkinsonsDiseaseAwareness #ParkinsonsDisease #NeurodegenerativeDisease #Neurodegeneration #Neuroinflammation #NeuroscienceCRO #CRO

During the recently concluded American Academy of Neurology 2024 Annual Meeting, Athira Pharma unveiled a poster entitled “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders.” The poster showcased preclinical data endorsing the advancement of Athira’s range of small molecule candidates aimed at the neurotrophic hepatocyte growth factor (HGF) system. These candidates include fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease. Explore more about Alzheimer's disease treatment market @ https://lnkd.in/gFZF9vVu #AthiraPharma #NeurodegenerativeDisorders #HGFSignaling #Alzheimers #ALS #Parkinsons #NeurologyConference

Immunic Therapeutics has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in relapsing-remitting Multiple Sclerosis (RRMS) in the peer-reviewed journal Neurology, Neuroimmunology and Neuroinflammation, an official journal of the American Academy of Neurology. After doses of 30mg and 45mg of vidofludimus calcium showed “robust activity” on multiple endpoints, the EMPhASIS trial enrolled patients to receive a lower dose of vidofludimus calcium to further investigate the dose-response relationship by extending the trial to a broader dose range. More at #Proactive #ProactiveInvestors #NASDAQ #IMUX http://ow.ly/JuVz105riFx

🧠 A new publication from our research group Neuroimmunology at the Department of Neurology/Goethe-University. ❓ Which biomarkers should be used for disease/treatment monitoring in the context of Multiple Sclerosis (MS) and other neuroinflammatory disorders? 📊 Of course, first of all, those which are closely associated with disease activity or central nervous system (CNS) injury. Meanwhile there are plenty of them, for example: neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCHL1) and total tau (tTAU). 👨🔬 However: biomarkers for disease/treatment monitoring should be easily measurable in blood. We can’t obtain every 3 months cerebrospinal fluid (CSF) from our patients since lumbar puncture is an invasive procedure. Fortunately, blood sampling is far less invasive and can be done regularly as a part of the clinical routine. 📈 Therefore: biomarker values measured in blood should estimate correctly cerebrospinal fluid (CSF) concentrations! ✅ In our just recently accepted for publication in "Multiple Sclerosis and Related Disorders" paper “Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis” (Open Access, see attachment/link), we demonstrated in 183 patients with MS, other neuroinflammatory disorders and somatoform controls that serum NfL and GFAP serve as adequate substitutes for CSF levels with NfL showing far more robust serum/CSF correlations compared to GFAP. ✅ Furthermore, serum and CSF NfL levels (but not other biomarkers) were able to differentiate between MS and somatoform diseases. ⭕ No significant correlations for UCHL1 and tTAU in serum and CSF were found, suggesting that serum measurements of those two biomarkers do not reflect adequately CSF concentrations in MS and neuroinflammation. 💪 Many thanks to Dr. med. Kimberly Körbel (first author of the paper), Dr. med. Michelle Maiworm and everyone else from our lab who contributed to this paper. Our thanks go also to our colleagues in Mainz, Eltville and Ludwigsburg whose support is greatly appreciated. 🤓 https://lnkd.in/eXqYd7qJ

#WorldBrainDay is celebrated annually on July 22. It is also known as International Brain Day The World Federation of Neurology (WFN) established World Brain Day in 2014. The date of July 22 was chosen because it was the day the WFN was founded in 1957. The day has been celebrated for the past nine years. It has helped to raise awareness and generate advocacy around the world. It is a dangerous disease, which occurs when cells grow at an abnormal rate to form a mass of abnormal cells inside the brain. A #braintumor can occur in the brain tissue and may be a life-threatening disease for people however it can be treatable completely. If brain tumor may occur inside the brain and is known as primary #brain tumors and sometimes, #cancer may spread to the brain from several. website: www.medzsupplier.com for inquiry : sales@medzsupplier.com Call: Or Chat +91 98 98972449

#transcript Alon Ben-Noon, CEO and board member of NeuroSense Therapeutics, is taking a unique approach to treating neurodegenerative diseases by targeting core pathologies and combining molecules to address various mechanisms. NeuroSense has seen positive clinical trial results for ALS using their lead compound PrimeC, which showed a reduction in disease progression. Research indicates the potential for this approach to be applied to other neurodegenerative diseases like Alzheimer's and Parkinson's.   #NeuroSense #ALS #Parkinsons #Alzheimers #NeurodegenerativeDiseases NeuroSense-TX.com https://lnkd.in/gHxWFNkN